CalciMedica ( (CALC) ) just unveiled an update.
CalciMedica, Inc. has appointed Stephen Bardin as its new CFO following Dan Geffken’s resignation. Bardin, with extensive experience in the biopharmaceutical sector, including roles at ATAI Life Sciences and BridgeBio Pharma, will receive a base salary of $380,000, a signing bonus, and stock options as part of his compensation package. His appointment is effective after the company’s quarterly SEC filing, and he is eligible for severance benefits if terminated without cause.
For an in-depth examination of CALC stock, go to TipRanks’ Stock Analysis page.
